Intra-abdominal infections: Etiology, epidemiology, microbiological diagnosis and antibiotic resistance

Journal of Chemotherapy

Volumn 21, Issue SUPPL. 1, 2009, Pages 5-11

  Nicoletti, G ^a   Nicolosi, D ^a   Rossolini, G M ^b   Stefani, S ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Antimicrobial resistance; Intra abdominal infections; Resistance to antimicrobial agents

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ABDOMINAL SURGERY; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTEROIDES; CANDIDA; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; FOREIGN BODY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INTESTINE FLORA; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS; COMMUNICABLE DISEASE; DIGESTIVE SYSTEM DISEASE; INFECTION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DIGESTIVE SYSTEM DISEASES; DRUG RESISTANCE, MICROBIAL; HUMANS; INFECTION;

EID: 70350489407     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.supplement-1.5     Document Type: Review

References (34)

1. Stijn B, De Waele JJ. Critical Issues in the clinical management of complicated intra-abdominal infections. Drugs 2005; 65: 1611-1620.
2. Swenson RM, Lorber B, Michaelson TC et al. The bacteriology of intraabdominal infections. Arch Surg 1974; 109(3): 398-9.
3. Van der Waaij D. Colonization resistance of the digestive tract: clinical consequences and implications. J Antimicrob Chemother 1982; 10: 263-270.
4. Laterre PF, Colardyn F, Delmee M, de Waele J, Legrand CL, Van Eldere J et al. Antimicrobial therapy for intra-abdominal infections: guidelines from the infectious diseases advisory board. Acta Chir Belga 2006; 106: 2-21.
5. Nicoletti G, Schito G, Fadda G, Boros S, Nicolosi D, Marchese A, et al. Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital settings. J Chemother 2006; 18 (8): 24-37.
6. Solomkin JS, Yellin AE, Rotsein OD, Nicolas V, Dellinger EP, Tellado JM, et al. Ertapenem versus piperadllin/tazobactam in the treatment of complicated intra-abdominal infections. Ann Surg 2003; 237: 235-245.
7. Seguin P, Laviolle B, Chavanaz C, Donnio PY, Gautier-Leferisf AL, Campion JP, et al. Factors associated with mutlidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 2006; 12: 980-985.
8. Montravers P, Mohler J, Saint Julien L, Carbon C. Evidence of the proinflammatory role of Enterococcus faecalis in polymicrobial peritonitis in rats. Infect Immun 1997; 65: 144-149.
9. Borbone S, Cascone C, Santagati M, Mezzatesta ML, Stefani S. The bactericidal activity of ertapenem against major intra-abdominal pathogens. Int J Antimicrob Agents 2006; 28: 396-401.
10. Turner PJ, Greenhalgh JM, Edwards JR, McKellar J. The MYSTIC (meropenem yearly susceptibility test information collection) programme. Int J Antimicrob Agents 1999; 13: 117-125.
11. Pfaller MA, Jones RN. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. J Antimicrob Chemother 2000; 46: 25-37.
12. Rossi F, Baquero F, Hsueh PR, Paterson DL, Bochicchio GV, Snyder TA, et al. In vitro susceptibilities of aerobic and anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006; 58: 205-210.
13. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G and The Italian ESBL Study Group. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to b-lactams and other antimicrobial drugs. Antimicrob Agents Chemother. 2002; 46:196-202.
14. Luzzaro F, Mezzatesta ML, Mugnaioli C, Perilli MG, Stefani S, Amicosante G et al. Trends in production of extended-spectrum beta-lactamases among Enterobacteria of medical interest: report of the second Italian Nationwide Survey. J Clin Microbiol 2006; 44: 1659-1664.
15. Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. Emergence and antibiotic resistant bacteria in case of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial chemotherapy. Clin Infect Dis 1996; 23: 486-494.
16. Stefani S. Emergence of multi-drug resistant Gram-positive bacteria and new active antibiotics. Curr Med Chem - Anti-Infective Agents 2005; 4: 235-257.
17. Stefani S, Varaldo PE. Epidemiology of MRSA in Europe. Clin Microbiol Infect 2003; 9(12): 1179-1186.
18. Mato R, Campanile F, Stefani S, Crisostomo MI, Santagati M, Santos Sanchez I, et al. Clonal types and multidrug resistance patterns of methicillin-resistant Staphylococcus aureus (MRSA) recovered in Italy during the 1990s. Microbial Drug Resistance 2004; 10: 106-113.
19. Grundmann H, Aires de Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health treat. Lancet 2006; 368: 874-885.
20. th ed. ASM Press, Washington, DC. 2003: 41-67.
21. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006; 6: 629-640.
22. Perichon B, Courvalin P, Galimand M. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob Agents Chemother 2007; 51, Epub ahead of print.
23. Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother. 2006; 50: 2872-2874.
24. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. Prevalence in the United States of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother 2006; 50: 3953-3955.
25. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18(8): 57-86.
26. Elliott E, Brink AJ, van Greune J, Els Z, Woodford N, Turton J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum b-lactamase. Clin Infect Dis 2006; 42: 95-98.
27. Livermore DM, Woodford N. The b-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006;. 14: 13-20.
28. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50: 3479-3484.
29. Morosini MI, Garcia-Castillo M, Coque TM, Valverde A, Novais A, Loza E, et al. Antibiotic co-resistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother. 2006; 50: 2695-2699.
30. Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother. 2006; 50: 3166-3169.
31. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect. 2005; 11 S4: 17-32.
32. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with b-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002; 46: 2920-2925.
33. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006; 43: S49-56.
34. Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, Dupont H. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother. 2009; 63(4):785-94